NIH officials say they found no safety concerns regarding Eli Lilly's antibody treatment but that there was no difference between patients receiving the drug and those getting a placebo.
Etiam at libero iaculis, mollis justo non, blandit augue. Vestibulum sit amet sodales est, a lacinia ex. Suspendisse vel enim sagittis, volutpat sem eget, condimentum sem.
0 comments: